@entity3988 and @entity3371 alone or in combination for treatment of mild to moderate systemic XXXX .

@entity3988 @entity1 @entity3371 @entity101
The efficacy and safety of sustained-release @entity3988 , 60 to 180 mg twice daily, was compared with that of @entity3371 , 25 to 75 mg twice daily, alone and in combination, in 132 @entity1 with mild to moderate essential @entity101 (supine diastolic blood pressure [BP] 95 to 114 mm Hg). All @entity1 received placebo for 4 to 6 weeks, followed by randomization to @entity3988 or @entity3371 during the double-blind monotherapy phase. Either study drug was titrated over 6 weeks to achieve a goal supine diastolic BP reduction of at least 10 mm Hg and a diastolic BP of less than 90 mm Hg. @entity1 achieving the goal BP reduction were maintained on monotherapy for an additional 8 weeks. @entity1 not achieving the treatment goal after 8 weeks with either drug alone received the other drug in combination, titrated to achieve goal BP response. Both drugs lowered BP significantly and, at the doses used, @entity3988 had a greater effect on diastolic BP than did @entity3371 . The mean changes from baseline at week 8 were -10.6 and -7.3 mm Hg, respectively, (p = 0.01). Goal BP was achieved in 38% of @entity1 taking @entity3988 monotherapy and in 34% of @entity1 taking @entity3371 monotherapy. There were no significant differences between @entity3988 and @entity3371 in diastolic or systolic BP reductions by race or age. The addition of alternate therapy for non-goal achievers at week 8 resulted in significant reductions in diastolic and systolic BP by week 16.(ABSTRACT TRUNCATED AT 250 WORDS)
